{"product_id":"recombinant-human-gm-csf-protein-bhp22200018","title":"Recombinant Human GM-CSF Protein","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}.bhp-desc .bhp-app-wrap{overflow-x:auto}.bhp-desc .bhp-app-table{width:100%;border-collapse:collapse;margin:12px 0 18px;font-size:14px}.bhp-desc .bhp-app-table th{background:#e8f0fb;color:#003366;text-align:left;padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-app-table td{padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eRecombinant Protein · Cytokine\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRecombinant Human GM-CSF Protein\u003c\/strong\u003e is a full-length, glycosylated monomer expressed in \u003cstrong\u003ehuman cells\u003c\/strong\u003e. It is manufactured in an animal-free, xeno-free and tag-free format and supplied lyophilized without carrier protein, at \u0026gt;95% purity by SDS-PAGE and endotoxin \u0026lt;0.5 EU\/µg.\u003c\/p\u003e\n\u003cp\u003eGM-CSF is widely used with IL-4 to generate immature monocyte-derived dendritic cells, and in studies of myeloid progenitor survival, proliferation and differentiation, antigen presentation, cytokine production and GM-CSF receptor signaling. Expression in human cells supports mammalian folding and glycosylation. Activity is confirmed by TF-1 cell proliferation.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eExpression system: Human cells · Tag-free · Animal-free\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eGM-CSF (CSF2) is a four-helix-bundle cytokine produced by activated T cells, macrophages, endothelial cells and stromal cells. Binding to its receptor complex triggers JAK2\/STAT5, MAPK and PI3K signaling, which supports survival, proliferation and functional maturation of myeloid progenitors and mature myeloid cells.\u003c\/p\u003e\n\u003cp\u003eIn vitro, GM-CSF is a standard factor for monocyte-derived dendritic-cell generation, often together with IL-4, and for studying granulocyte and macrophage lineage responses. Results depend on cell source, cytokine dose, exposure time and companion signals.\u003c\/p\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cp\u003eGM-CSF supports responsive myeloid populations, from progenitors to monocyte-derived dendritic cells. The table summarizes where it is typically placed in a workflow; it is a planning guide, not a universal protocol.\u003c\/p\u003e\n\u003cdiv class=\"bhp-app-wrap\"\u003e\u003ctable class=\"bhp-app-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRole of GM-CSF\u003c\/th\u003e\n\u003cth\u003eCompanion signals and context\u003c\/th\u003e\n\u003cth\u003eSuggested readouts\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonocyte-derived dendritic cells\u003c\/td\u003e\n\u003ctd\u003eSupports early differentiation\u003c\/td\u003e\n\u003ctd\u003eIL-4; later a maturation cocktail\u003c\/td\u003e\n\u003ctd\u003eCD11c, HLA-DR, CD80\/CD86, morphology and antigen presentation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyeloid progenitor culture\u003c\/td\u003e\n\u003ctd\u003eSurvival and lineage support\u003c\/td\u003e\n\u003ctd\u003eSCF, IL-3 or lineage-specific factors\u003c\/td\u003e\n\u003ctd\u003eCell count, viability, CFU, CD14\/CD15\/CD33\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTF-1 bioassay\u003c\/td\u003e\n\u003ctd\u003eReceptor-dependent proliferation\u003c\/td\u003e\n\u003ctd\u003eDefined low-serum assay conditions\u003c\/td\u003e\n\u003ctd\u003eDose response, viability and proliferation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyeloid signaling\u003c\/td\u003e\n\u003ctd\u003eAcute receptor activation\u003c\/td\u003e\n\u003ctd\u003eTime-course and pathway controls\u003c\/td\u003e\n\u003ctd\u003epSTAT5, pERK, pAKT and target genes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003ePlanning considerations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDefine the responsive cell stage and confirm that the cells express the GM-CSF receptor.\u003c\/li\u003e\n\u003cli\u003eBegin with a validated protocol, then run a dose response for the actual cell source, medium and endpoint.\u003c\/li\u003e\n\u003cli\u003eControl timing and companion factors such as IL-4, since signal order and duration can change lineage or functional outcomes; include no-factor, vehicle and pathway-response controls.\u003c\/li\u003e\n\u003cli\u003eMeasure phenotype and function rather than cell number alone. No EC50 or universal working concentration applies without lot- or protocol-specific evidence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eProtein Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eGM-CSF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative names\u003c\/th\u003e\n\u003ctd\u003eCSF2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression system\u003c\/th\u003e\n\u003ctd\u003eHuman cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStructure\u003c\/th\u003e\n\u003ctd\u003eGlycosylated monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProtein family\u003c\/th\u003e\n\u003ctd\u003eFour-helix-bundle cytokine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression region\u003c\/th\u003e\n\u003ctd\u003eFull length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003ctd\u003eTag-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAnimal origin\u003c\/th\u003e\n\u003ctd\u003eAnimal-free \/ xeno-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular weight\u003c\/th\u003e\n\u003ctd\u003e15–36 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eEndotoxin level\u003c\/th\u003e\n\u003ctd\u003e\u0026lt;0.5 EU\/µg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eLyophilized from a 0.2 µm-filtered solution in PBS without carrier protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiological activity\u003c\/th\u003e\n\u003ctd\u003eStimulation of human TF-1 cell proliferation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eApplications\u003c\/th\u003e\n\u003ctd\u003eStem Cell Differentiation, Immunotherapy, Hematopoietic Differentiation, Antigen Presentation Assay, Cell Proliferation, Cell Signaling Studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eBiological Activity \u0026amp; Quality Control\u003c\/h2\u003e\n\u003cp\u003eBiological activity is measured by dose-dependent stimulation of human TF-1 cell proliferation.\u003c\/p\u003e\n\u003cp\u003eLot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.\u003c\/p\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eBriefly centrifuge the vial before opening.\u003c\/li\u003e\n\u003cli\u003eReconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.\u003c\/li\u003e\n\u003cli\u003eMix gently and prepare single-use aliquots.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eStorage \u0026amp; Shipping\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eAs supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003ePlease contact us to confirm shipping conditions for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eSelected References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eWang X, et al. (2018) Dendritic Cells Are Critical for the Activation and Expansion of Vδ2+ T Cells After Allogeneic Hematopoietic Transplantation. Front Immunol 9:2528. \u003ca href=\"https:\/\/doi.org\/10.3389\/fimmu.2018.02528\" target=\"_blank\" rel=\"noopener\"\u003e10.3389\/fimmu.2018.02528\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eWong GG, Witek JS, Temple PA, et al. (1985) Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 228:810-815. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.3923623\" target=\"_blank\" rel=\"noopener\"\u003e10.1126\/science.3923623\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003evan de Laar L, Coffer PJ, Woltman AM (2012) Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 119:3383-3393. \u003ca href=\"https:\/\/doi.org\/10.1182\/blood-2011-11-370130\" target=\"_blank\" rel=\"noopener\"\u003e10.1182\/blood-2011-11-370130\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eZhan Y, Lew AM, Chopin M (2019) The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game. Front Immunol 10:2679. \u003ca href=\"https:\/\/doi.org\/10.3389\/fimmu.2019.02679\" target=\"_blank\" rel=\"noopener\"\u003e10.3389\/fimmu.2019.02679\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\u003cp style=\"margin:0\"\u003eHandle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.\u003c\/p\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cem\u003eFor research use only. Not for diagnostic or therapeutic use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"StemImmune LLC","offers":[{"title":"10 ug","offer_id":67641421496685,"sku":"HHM-GM-0010","price":109.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":67641430737261,"sku":"HHM-GM-0100","price":866.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/GMCSF-500x500.png?v=1791572807","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-gm-csf-protein-bhp22200018","provider":"BioHippo","version":"1.0","type":"link"}